NCT02220153 - A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy

Interventions

BIOLOGICAL

UCB7665 Intravenous 1

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"

BIOLOGICAL

UCB7665 Intravenous 2

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"

BIOLOGICAL

UCB7665 Intravenous 3

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"

BIOLOGICAL

UCB7665 Intravenous 4

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"

BIOLOGICAL

UCB7665 Intravenous 5

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"

BIOLOGICAL

UCB7665 Subcutaneous 1

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"

BIOLOGICAL

UCB7665 Subcutaneous 2

"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"

BIOLOGICAL

Intravenous Placebo

"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"

BIOLOGICAL

Subcutaneous Placebo

"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"

Trial Locations (1)

001, Harrow